 Atypical Hemolytic Uremic Syndrome
"Atypical Hemolytic Uremic Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An hereditary hemolytic uremic syndrome associated with variations in the gene that encodes COMPLEMENT FACTOR H, or the related proteins CFHR1 and CFHR3. Disease often progresses to CHRONIC KIDNEY FAILURE without the prodromal symptoms of ENTEROCOLITIS and DIARRHEA that characterize typical hemolytic uremic syndrome.
| Descriptor ID |
D065766
|
| MeSH Number(s) |
C12.777.419.936.463.500 C13.351.968.419.936.463.500 C15.378.071.141.610.500 C15.378.140.855.925.500.500
|
| Concept/Terms |
Atypical Hemolytic Uremic Syndrome- Atypical Hemolytic Uremic Syndrome
- Non-Stx-Hus
- Non Stx Hus
- Non-Shiga-Like Toxin-Associated HUS
- HUS, Non-Shiga-Like Toxin-Associated
- HUSs, Non-Shiga-Like Toxin-Associated
- Non Shiga Like Toxin Associated HUS
- Non-Shiga-Like Toxin-Associated HUSs
- Toxin-Associated HUS, Non-Shiga-Like
- Toxin-Associated HUSs, Non-Shiga-Like
- Hemolytic Uremic Syndrome, Atypical
- Nonenteropathic HUS
- HUS, Nonenteropathic
- HUSs, Nonenteropathic
- Nonenteropathic HUSs
- Atypical Hemolytic-Uremic Syndrome
- Atypical Hemolytic-Uremic Syndromes
- Hemolytic-Uremic Syndrome, Atypical
- Hemolytic-Uremic Syndromes, Atypical
- Syndrome, Atypical Hemolytic-Uremic
- Syndromes, Atypical Hemolytic-Uremic
|
Below are MeSH descriptors whose meaning is more general than "Atypical Hemolytic Uremic Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Atypical Hemolytic Uremic Syndrome".
This graph shows the total number of publications written about "Atypical Hemolytic Uremic Syndrome" by people in this website by year, and whether "Atypical Hemolytic Uremic Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2020 | 1 | 1 | 2 | | 2022 | 2 | 1 | 3 | | 2023 | 3 | 0 | 3 | | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Atypical Hemolytic Uremic Syndrome" by people in Profiles.
-
Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, Java A, van de Kar NCAJ, Kavanagh D, Leung N, Licht C, Noris M, O'Shaughnessy MM, Parikh SV, Peyandi F, Remuzzi G, Smith RJH, Sperati CJ, Waldman M, Walker P, Vivarelli M. An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group. Kidney Int. 2024 Sep; 106(3):326-336.
-
McBride HJ, Frazer-Abel A, Thiemann S, Lehto SG, Hutterer KM, Liu J. Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD. Ann Hematol. 2023 Dec; 102(12):3299-3309.
-
Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
-
Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 09; 12(9):e230036.
-
Gange WS, Haghighi A, Toy BC. PURTSCHER-LIKE RETINOPATHY ASSOCIATED WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME: CASE REPORT AND REVIEW OF OUTCOMES. Retin Cases Brief Rep. 2023 Mar 01; 17(2):154-159.
-
Thurman JM, Harrison RA. The susceptibility of the kidney to alternative pathway activation-A hypothesis. Immunol Rev. 2023 01; 313(1):327-338.
-
Stenson EK, Kendrick J, Dixon B, Thurman JM. The complement system in pediatric acute kidney injury. Pediatr Nephrol. 2023 05; 38(5):1411-1425.
-
Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther. 2022 Jul; 47(7):1081-1087.
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
-
Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol. 2020 12; 128:175-187.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|